Nicox SA
PAR:COX

Watchlist Manager
Nicox SA Logo
Nicox SA
PAR:COX
Watchlist
Price: 0.579 EUR -0.52% Market Closed
Market Cap: 28.9m EUR

Net Margin
Nicox SA

-848.6%
Current
-531%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-848.6%
=
Net Income
-27.8m
/
Revenue
3.3m

Net Margin Across Competitors

No Stocks Found

Nicox SA
Glance View

Market Cap
28.8m EUR
Industry
Biotechnology

Nicox SA is an ophthalmology company. The company is headquartered in Valbonne, Paca. The company is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The firm has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). The company has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.

COX Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-848.6%
=
Net Income
-27.8m
/
Revenue
3.3m
What is the Net Margin of Nicox SA?

Based on Nicox SA's most recent financial statements, the company has Net Margin of -848.6%.

Back to Top